Annuncio • Aug 06
Transmedics Group, Inc. Provides Earnings Guidance for Full Year 2026 TransMedics Group, Inc. provided earnings guidance for full year 2026. For the period, the company expects raising the low end of its revenue guidance to a range of $737 million to $757 million. TransMedics' full year 2026 revenue guidance as reported on May 5, 2026 was previously in the range of $727 million to $757 million. Reported Earnings • Aug 05
Second quarter 2026 earnings released: EPS: US$0.42 (vs US$1.03 in 2Q 2025) Second quarter 2026 results: EPS: US$0.42 (down from US$1.03 in 2Q 2025). Revenue: US$189.9m (up 21% from 2Q 2025). Net income: US$14.7m (down 58% from 2Q 2025). Profit margin: 7.7% (down from 22% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annuncio • Jul 22
TransMedics Group, Inc. to Report Q2, 2026 Results on Aug 04, 2026 TransMedics Group, Inc. announced that they will report Q2, 2026 results After-Market on Aug 04, 2026 Valuation Update With 7 Day Price Move • May 12
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to €54.18, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Medical Equipment industry in Germany. Total loss to shareholders of 24% over the past three years. Annuncio • May 07
TransMedics Group, Inc. Reiterates Earnings Guidance for the Financial Year 2026 TransMedics Group, Inc. reiterated earnings guidance for the financial year 2026. For the year, the company expects revenue guidance to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company's prior year revenue. New Risk • May 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (€654k sold). Reported Earnings • May 06
First quarter 2026 earnings released: EPS: US$0.21 (vs US$0.76 in 1Q 2025) First quarter 2026 results: EPS: US$0.21 (down from US$0.76 in 1Q 2025). Revenue: US$173.9m (up 21% from 1Q 2025). Net income: US$7.32m (down 72% from 1Q 2025). Profit margin: 4.2% (down from 18% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Annuncio • May 02
Montreal Heart Institute and Chu Sainte-Justine Debut Transmedics Organ Care System Heart Montreal Heart Institute and CHU Sainte-Justine are set to begin using a cutting-edge device that will expand access to cardiac transplantation. The TransMedics Organ Care System (OCS) Heart, a device designed to preserve donor hearts and transport them under near-physiological conditions, is making its debut at the Montreal Heart Institute (MHI) and CHU Sainte-Justine. With standard methods, a heart can only be kept on ice for four to six hours. The OCS Heart is a perfusion system that safely keeps the heart beating and oxygenated for longer periods of time. As a result, it increases the number of donated organs that can be transported, thereby improving the odds of an adult or pediatric patient on the waiting list of receiving a transplant. Many patients are waiting for a life-saving transplant procedure at the MHI and CHU Sainte-Justine. In fact, a transplant candidate in Quebec will spend an average of 204 days on a waiting list – a period defined by constant uncertainty. Moreover, the number of people awaiting a transplant increased from 856 to 898 between 2024 and 2025. Of this number, 67 were waiting for a heart transplant in 2025. A heart transplant requires a close collaboration between myriad parties. Transplant Québec plays a pivotal role in coordinating organ donation, managing waiting lists, and overseeing organ recoveries across the province. The OCS Heart will be used to facilitate these processes. It will provide more flexibility for transporting and evaluating donor organs, in particular when recipients are located a long distance from the point of collection. Annuncio • Apr 23
TransMedics Group, Inc. Provides Update On Ongoing Clinical Programs And Unveils Controlled Hypothermic Organ Preservation System TransMedics Group, Inc. provided an update on its ongoing clinical programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting in Toronto, Canada. At the meeting, TransMedics will unveil its new controlled, active cooling preservation device, the Controlled Hypothermic Organ Preservation System (CHOPS), aimed at facilitating the enrollment of the control arms of the OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials. CHOPS is a true active cooling device that provides a consistent and stable controlled cold storage environment for donor organs at a variety of temperature ranges that are established based on the recipient transplant program's preferences. In comparison, other current cold storage techniques use phase changing material that makes it difficult to control or adjust temperatures. CHOPS will be regulated by the U.S. Food and Drug Administration as a new, stand-alone device for controlled hypothermic preservation. TransMedics will submit an Investigation Device Exemption amendment to allow CHOPS to serve as the control arm for both Part B of ENHANCE Heart and DENOVO Lung Trials. The FDA granted full approval of TransMedics' Investigation Device Exemption for the Next-Generation OCS ENHANCE Heart trial in February 2026 and of the company's Investigation Device Exemption for its Next-Generation OCS DENOVO Lung trial in January 2026. Part B of the ENHANCE trial is designed to assess the superiority of OCS Heart perfusion in donation after brain death cases when compared to donation after brain death cases using static cold storage methods. The OCS DENOVO trial is designed to assess the superiority of OCS Lung perfusion in donation after brain death and donation after circulatory death cases when compared to cases using static cold storage methods. Annuncio • Apr 22
TransMedics Group, Inc. to Report Q1, 2026 Results on May 05, 2026 TransMedics Group, Inc. announced that they will report Q1, 2026 results After-Market on May 05, 2026 Annuncio • Apr 13
TransMedics Group, Inc., Annual General Meeting, May 20, 2026 TransMedics Group, Inc., Annual General Meeting, May 20, 2026. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €81.70, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total returns to shareholders of 17% over the past three years. Recent Insider Transactions • Mar 06
Key Executive recently sold €353k worth of stock On the 2nd of March, Nicholas Corcoran sold around 3k shares on-market at roughly €119 per share. This transaction amounted to 9.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Nicholas' only on-market trade for the last 12 months. Reported Earnings • Feb 25
Full year 2025 earnings released: EPS: US$5.60 (vs US$1.07 in FY 2024) Full year 2025 results: EPS: US$5.60 (up from US$1.07 in FY 2024). Revenue: US$605.5m (up 37% from FY 2024). Net income: US$190.3m (up 437% from FY 2024). Profit margin: 31% (up from 8.0% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Annuncio • Feb 25
TransMedics Group, Inc. Provides Earnings Guidance for the Financial Year 2026 TransMedics Group, Inc. provided earnings guidance for the financial year 2026. For the year, the company expects total revenue to be in the range of $727 million to $757 million, which represents 20% to 25% growth compared to the company's prior year revenue. Annuncio • Feb 11
TransMedics Group, Inc. to Report Q4, 2025 Results on Feb 24, 2026 TransMedics Group, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026 Annuncio • Feb 10
TransMedics Group, Inc. Receives Full and Unconditional FDA Ide Approval for Next-Generation OCS Heart Enhance Trial TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This follows full FDA approval of the company's Next-Generation OCS DENOVO Lung IDE trial in January 2026 and conditional IDE approval for the ENHANCE Heart trial in August 2025. The ENHANCE trial is a two-part clinical trial. Part A is designed to support prolonged heart perfusion using OCS™? Heart System. Part B is intended to demonstrate the superiority of OCS Heart perfusion in donation after brain death (DBD) cases when compared to DBD cases using static cold storage methods. Some of the key factors that could cause actual results to differ include: the fluctuation of financial results from quarter to quarter; ability to attract, train, and retain key personnel; existing and any future indebtedness, including the ability to scale its manufacturing and sterilization capabilities to meet increasing demand for the products; the rate and degree of market acceptance of the OCS; ability to educate patients, surgeons, transplant centers and private and public payors of benefits offered by the OCS; ability to maintain regulatory approvals or clearances for the OCS products in the United States, the European Union, and other select jurisdictions worldwide; ability to adequately respond to Food and Drug Administration ("FDA"), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation reforming the U.S. healthcare system, Organ Procurement and Transplantation Network ("OPTN"), or the FDA; the performance of third-party suppliers and manufacturers; use of third parties to transport donor organs and medical personnel for the NOP and the ability to maintain and grow logistics capabilities to support NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for aviation transportation services or other acquisitions, joint ventures or strategic investments; ability to maintain Federal Aviation Administration ("FAA") or other regulatory licenses or approvals for aircraft transportation services; price increases of the components of the products and maintenance, parts and fuel for aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against the information technology infrastructure; the economic, political and other risks associated with our foreign operations; ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid claims that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of any future U.S. government shutdowns; the extent and success of competing products or procedures that are or may become available; ability to service our 1.50% convertible senior notes, due 2028; the impact of any product calls or improper use of our products; the estimates regarding revenues; and our estimates regarding revenues; our existing and any future OCS™?; and our existing and any future future U.S. government government shutdowns; the ability to maintain the OCS Heart perfusion in donations after brain death (DBD). Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €113, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 20x in the Medical Equipment industry in Germany. Total returns to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €199 per share. Recent Insider Transactions • Nov 20
Founder recently bought €863k worth of stock On the 17th of November, Waleed Hassanein bought around 9k shares on-market at roughly €98.29 per share. This transaction amounted to 1.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Waleed has been a buyer over the last 12 months, purchasing a net total of €2.6m worth in shares. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: US$0.71 (vs US$0.13 in 3Q 2024) Third quarter 2025 results: EPS: US$0.71 (up from US$0.13 in 3Q 2024). Revenue: US$143.8m (up 32% from 3Q 2024). Net income: US$24.3m (up 477% from 3Q 2024). Profit margin: 17% (up from 3.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Annuncio • Oct 30
TransMedics Group, Inc. Raises Revenue Guidance of Its Full Year 2025 TransMedics Group, Inc. raised revenue guidance of its full year 2025. For the period, the company raising the midpoint and narrowing the range of its full year 2025 revenue guidance to $595 million to $605 million, which represents 36% growth at the midpoint compared to the company's prior year revenue. TransMedics' full year 2025 revenue guidance as reported on July 30, 2025 was previously in the range of $585 million to $605 million. Annuncio • Oct 16
TransMedics Group, Inc. to Report Q3, 2025 Results on Oct 29, 2025 TransMedics Group, Inc. announced that they will report Q3, 2025 results After-Market on Oct 29, 2025 Recent Insider Transactions • Aug 10
Founder recently bought €1.7m worth of stock On the 7th of August, Waleed Hassanein bought around 17k shares on-market at roughly €101 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Waleed's only on-market trade for the last 12 months. Annuncio • Aug 05
TransMedics Group, Inc. Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial. The ENHANCE trial is a two-part clinical trial. Part A is designed to support prolonged heart perfusion using OCS™? Heart System. Part B is intended to demonstrate the superiority of OCS Heart perfusion in donation after brain death (DBD) cases when compared to DBD cases using static cold storage methods. Part B is intended to support the potential expansion of OCS Heart clinical indications to include DBD hearts that are not currently eligible for OCS perfusion and preservation. The trial's total sample size, across both Part A and Part B, is expected to exceed 650 patients. TransMedics believes this would constitute the largest heart preservation for transplant trial ever, worldwide. Reported Earnings • Jul 31
Second quarter 2025 earnings released: EPS: US$1.03 (vs US$0.37 in 2Q 2024) Second quarter 2025 results: EPS: US$1.03 (up from US$0.37 in 2Q 2024). Revenue: US$157.4m (up 38% from 2Q 2024). Net income: US$34.9m (up 186% from 2Q 2024). Profit margin: 22% (up from 11% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Annuncio • Jul 31
TransMedics Group, Inc. Revises Revenue Guidance for the Full Year 2025 TransMedics Group, Inc. revised revenue guidance for the full year 2025. The company is raising its full year 2025 revenue guidance to be in the range of $585 million to $605 million, which represents 35% growth at the midpoint compared to the company's prior year revenue. The company’s full year 2025 revenue guidance as reported on May 8, 2025, was previously in the range of $565 million to $585 million. Board Change • Jul 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • Jul 17
TransMedics Group, Inc. to Report Q2, 2025 Results on Jul 30, 2025 TransMedics Group, Inc. announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • May 10
First quarter 2025 earnings released: EPS: US$0.76 (vs US$0.37 in 1Q 2024) First quarter 2025 results: EPS: US$0.76 (up from US$0.37 in 1Q 2024). Revenue: US$143.5m (up 48% from 1Q 2024). Net income: US$25.7m (up 111% from 1Q 2024). Profit margin: 18% (up from 13% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Annuncio • May 09
Transmedics Group, Inc. Revises Revenue Guidance for the Full Year 2025 TransMedics Group, Inc. revised revenue guidance for the full year 2025. For the year, the company expects revenue guidance to be in the range of $565 million to $585 million, which represents 30% growth at the midpoint compared to the company's prior year revenue. TransMedics' full year 2025 revenue guidance as reported on February 27, 2025 was previously in the range of $530 million to $552 million. Board Change • May 08
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • Apr 25
TransMedics Group, Inc. to Report Q1, 2025 Results on May 08, 2025 TransMedics Group, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Board Change • Apr 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Mar 25
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • Mar 01
TransMedics Group, Inc., Annual General Meeting, May 22, 2025 TransMedics Group, Inc., Annual General Meeting, May 22, 2025. Reported Earnings • Feb 28
Full year 2024 earnings released: EPS: US$1.07 (vs US$0.77 loss in FY 2023) Full year 2024 results: EPS: US$1.07 (up from US$0.77 loss in FY 2023). Revenue: US$441.5m (up 83% from FY 2023). Net income: US$35.5m (up US$60.5m from FY 2023). Profit margin: 8.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Annuncio • Feb 28
TransMedics Group, Inc. Provides Earnings Guidance for the Year 2025 TransMedics Group, Inc. provided earnings guidance for the year 2025. For the year, the company expects total revenue to be in the range of $530 million to $552 million, which represents 20% to 25% growth compared to the company's prior year revenue. Annuncio • Feb 16
Rosen Law Firm Files Securities Class Action Lawsuit Against TransMedics Group, Inc Rosen Law Firm announced it has filed a class action lawsuit on behalf of purchasers of the securities of TransMedics Group, Inc. between February 28, 2023 and January 10, 2025, both dates inclusive (the Class Period). The lawsuit seeks to recover damages for TransMedics investors under the federal securities laws. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants’ statements about TransMedics’ business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If wish to serve as lead plaintiff, must move the Court no later than April 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Annuncio • Feb 14
TransMedics Group, Inc. to Report Q4, 2024 Results on Feb 27, 2025 TransMedics Group, Inc. announced that they will report Q4, 2024 results After-Market on Feb 27, 2025 Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to €56.38, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to €73.12, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €68.20, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €72.88, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 22x in the Medical Equipment industry in Germany. Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: US$0.13 (vs US$0.78 loss in 3Q 2023) Third quarter 2024 results: EPS: US$0.13 (up from US$0.78 loss in 3Q 2023). Revenue: US$108.8m (up 64% from 3Q 2023). Net income: US$4.22m (up US$29.6m from 3Q 2023). Profit margin: 3.9% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Annuncio • Oct 29
TransMedics Group, Inc. Provides Revenue Guidance for the Full Year 2024 TransMedics Group, Inc. provided revenue guidance for the full year 2024. TransMedics continues to expect revenue for the full year 2024 to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company's prior year revenue. Annuncio • Oct 16
TransMedics Group, Inc. to Report Q3, 2024 Results on Oct 28, 2024 TransMedics Group, Inc. announced that they will report Q3, 2024 results After-Market on Oct 28, 2024 Recent Insider Transactions • Aug 11
Independent Chairman recently sold €2.9m worth of stock On the 8th of August, James Tobin sold around 20k shares on-market at roughly €146 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. James has been a net seller over the last 12 months, reducing personal holdings by €3.6m. Annuncio • Aug 02
TransMedics Group, Inc. Raises Revenue Guidance for the Year 2024 TransMedics Group, Inc. raises revenue guidance for the year 2024. For the period, the company expects revenue guidance to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company's prior year revenue. TransMedics' prior 2024 revenue guidance was $390 million to $400 million. Reported Earnings • Aug 01
Second quarter 2024 earnings released: EPS: US$0.37 (vs US$0.031 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.37 (up from US$0.031 loss in 2Q 2023). Revenue: US$114.3m (up 118% from 2Q 2023). Net income: US$12.2m (up US$13.2m from 2Q 2023). Profit margin: 11% (up from net loss in 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Annuncio • Jul 18
TransMedics Group, Inc. to Report Q2, 2024 Results on Jul 31, 2024 TransMedics Group, Inc. announced that they will report Q2, 2024 results After-Market on Jul 31, 2024 Recent Insider Transactions • May 06
Founder recently sold €1.4m worth of stock On the 2nd of May, Waleed Hassanein sold around 12k shares on-market at roughly €113 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Waleed has been a net seller over the last 12 months, reducing personal holdings by €2.0m. Annuncio • May 03
TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024 TransMedics Group, Inc. raised revenue guidance for the full year 2024. For the period, the company expects revenue to be in the range of $390 million to $400 million, which represents 61% to 66% growth compared to the company's prior year revenue. Company's prior 2024 revenue guidance was $360 million to $370 million. Reported Earnings • May 01
First quarter 2024 earnings released: EPS: US$0.37 (vs US$0.082 loss in 1Q 2023) First quarter 2024 results: EPS: US$0.37 (up from US$0.082 loss in 1Q 2023). Revenue: US$96.9m (up 133% from 1Q 2023). Net income: US$12.2m (up US$14.8m from 1Q 2023). Profit margin: 13% (up from net loss in 1Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Breakeven Date Change • May 01
Forecast breakeven date moved forward to 2024 The 7 analysts covering TransMedics Group previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$24.1m in 2024. Earnings growth of 77% is required to achieve expected profit on schedule. Annuncio • Apr 17
TransMedics Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024 TransMedics Group, Inc. announced that they will report Q1, 2024 results After-Market on Apr 30, 2024 New Risk • Apr 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Significant insider selling over the past 3 months (€258k sold). Annuncio • Apr 11
TransMedics Group, Inc., Annual General Meeting, May 23, 2024 TransMedics Group, Inc., Annual General Meeting, May 23, 2024, at 08:00 Eastern Standard Time. Agenda: To elect eight (8) directors, each to serve until the 2025 annual meeting of shareholders; to approve, on a non-binding advisory basis, the compensation paid to named executive officers; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2024; and to consider other business issues. Annuncio • Feb 29
Transmedics Group, Inc. Provides Revenue Guidance for the Full-Year 2024 TransMedics Group, Inc. provided revenue guidance for the full-year 2024. For the period, the company expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company's prior year revenue. Reported Earnings • Feb 27
Full year 2023 earnings released: US$0.77 loss per share (vs US$1.23 loss in FY 2022) Full year 2023 results: US$0.77 loss per share (improved from US$1.23 loss in FY 2022). Revenue: US$241.6m (up 159% from FY 2022). Net loss: US$25.0m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Breakeven Date Change • Feb 27
Forecast breakeven date moved forward to 2024 The 5 analysts covering TransMedics Group previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$17.1m in 2024. Earnings growth of 64% is required to achieve expected profit on schedule. Annuncio • Feb 13
TransMedics Group, Inc. to Report Q4, 2023 Results on Feb 26, 2024 TransMedics Group, Inc. announced that they will report Q4, 2023 results After-Market on Feb 26, 2024 Board Change • Feb 08
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Merilee Raines was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Breakeven Date Change • Dec 12
Forecast breakeven date pushed back to 2025 The 6 analysts covering TransMedics Group previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 28% per year to 2024. The company is expected to make a profit of US$726.0k in 2025. Average annual earnings growth of 64% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 02
Independent Chairman recently sold €638k worth of stock On the 28th of November, James Tobin sold around 10k shares on-market at roughly €63.83 per share. This transaction amounted to 4.1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was James' only on-market trade for the last 12 months. Annuncio • Nov 08
TransMedics Group, Inc. Updating Revenue Guidance for the Year 2023 TransMedics Group, Inc. updated revenue guidance for the year 2023. The company is updating its full-year 2023 revenue guidance to be in the range of $222 million to $230 million, which represents 138% to 146% growth compared to the company's prior year revenue. The company's prior 2023 revenue guidance was $180 million to $190 million. Breakeven Date Change • Nov 07
Forecast breakeven date pushed back to 2025 The 6 analysts covering TransMedics Group previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 86% per year to 2024. The company is expected to make a profit of US$34.9m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule. Reported Earnings • Nov 07
Third quarter 2023 earnings released: US$0.78 loss per share (vs US$0.25 loss in 3Q 2022) Third quarter 2023 results: US$0.78 loss per share (further deteriorated from US$0.25 loss in 3Q 2022). Revenue: US$66.4m (up 159% from 3Q 2022). Net loss: US$25.4m (loss widened 242% from 3Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Annuncio • Oct 24
TransMedics Group, Inc. to Report Q3, 2023 Results on Nov 06, 2023 TransMedics Group, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023 Reported Earnings • Aug 06
Second quarter 2023 earnings released: US$0.031 loss per share (vs US$0.41 loss in 2Q 2022) Second quarter 2023 results: US$0.031 loss per share (improved from US$0.41 loss in 2Q 2022). Revenue: US$52.5m (up 156% from 2Q 2022). Net loss: US$1.00m (loss narrowed 91% from 2Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Annuncio • Aug 05
TransMedics Group, Inc. Revises Revenue Guidance for the Year 2023 TransMedics Group, Inc. revised revenue guidance for the year 2023. The company is updating its full year 2023 revenue guidance to be in the range of $180 million to $190 million, which represents 93% to 103% growth compared to the company’s 2022 revenue. The company’s prior 2023 revenue guidance was $160 million to $170 million. Breakeven Date Change • Aug 04
Forecast breakeven date pushed back to 2025 The 6 analysts covering TransMedics Group previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 70% per year to 2024. The company is expected to make a profit of US$44.1m in 2025. Average annual earnings growth of 101% is required to achieve expected profit on schedule. Annuncio • Aug 02
TransMedics Group, Inc. (NasdaqGM:TMDX) signed a definitive agreement to acquire Summit Aviation. TransMedics Group, Inc. (NasdaqGM:TMDX) signed a definitive agreement to acquire Summit Aviation on August 1, 2023. Upon closing, Ben Walton, Founder of Summit, will join TransMedics as VP of Aviation Services. The deal is expected to close in the third quarter of 2023, subject to the satisfaction of closing conditions. Annuncio • Jul 27
TransMedics Group, Inc. Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary TransMedics Group, Inc. announced the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. Mr. Ranganath brings over 15 years of experience providing counsel in the life sciences and biotechnology tools industries. Throughout his career, he served multiple roles of increasing scope and responsibility at Waters Corporation. Most recently, Mr. Ranganath served as Vice President, Deputy General Counsel for Waters, managing legal affairs, and serving as a trusted advisor on Waters' strategic, tactical, and operational plans. Earlier in his career, he served as an attorney at Brown Rudnick LLP, representing life sciences and biotechnology companies on corporate and intellectual property matters. Mr. Ranganath holds a Juris Doctorate from Suffolk University Law School and a bachelor's degree in Computer Science from Worcester Polytechnic Institute. Annuncio • Jul 23
TransMedics Group, Inc. to Report Q2, 2023 Results on Aug 03, 2023 TransMedics Group, Inc. announced that they will report Q2, 2023 results After-Market on Aug 03, 2023 Recent Insider Transactions • Jul 11
Founder recently sold €567k worth of stock On the 3rd of July, Waleed Hassanein sold around 8k shares on-market at roughly €75.61 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Waleed has been a net seller over the last 12 months, reducing personal holdings by €1.5m. Breakeven Date Change • May 04
Forecast breakeven date moved forward to 2024 The 5 analysts covering TransMedics Group previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 55% to 2023. The company is expected to make a profit of US$8.05m in 2024. Average annual earnings growth of 64% is required to achieve expected profit on schedule. Reported Earnings • May 03
First quarter 2023 earnings released: US$0.082 loss per share (vs US$0.38 loss in 1Q 2022) First quarter 2023 results: US$0.082 loss per share (improved from US$0.38 loss in 1Q 2022). Revenue: US$41.6m (up 162% from 1Q 2022). Net loss: US$2.64m (loss narrowed 75% from 1Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Breakeven Date Change • Mar 24
Forecast to breakeven in 2025 The 5 analysts covering TransMedics Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 84% per year to 2024. The company is expected to make a profit of US$15.8m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule. 
